M. Capel

发表

A Comparison of Budesonide/Formoterol Maintenance and Reliever Therapy Versus Conventional Best Practice in Asthma Management in Spain

S. Quirce, V. Plaza, C. Barcina, 2011, The Journal of asthma : official journal of the Association for the Care of Asthma.

Is quality of life different between diabetic and non-diabetic people? The importance of cardiovascular risks

L. Rodríguez-Mañas, J. Oliva-Moreno, M. Capel, 2017, PloS one.

Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain

M. Capel, N. Manito, Carlos Escobar, 2021, Nefrología (English Edition).

Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain.

C. Escobar, M. Capel, N. Manito, 2021, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

Costs and healthcare utilisation of patients with chronic kidney disease in Spain

C. Escobar, M. Capel, N. Manito, 2021, BMC Health Services Research.

Risk of outcomes in a Spanish population with heart failure

M. Capel, N. Manito, Carlos Escobar, 2022, REC: CardioClinics.

A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus

M. Capel, N. Zozaya, S. Simón, 2019, Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish.

Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment

I. Oyagüez, M. Capel, L. Lindner, 2018, Clinical Drug Investigation.

The 2021 European Society of Cardiology Cardiovascular Disease Prevention Guidelines: adding albuminuria to the SCORE scale increases the prevalence of very high/high cardiovascular risk among patients with chronic kidney disease

M. Capel, N. Manito, Carlos Escobar, 2022, Clinical kidney journal.

Including KDIGO cardiovascular risk stratification into SCORE scale could improve the accuracy to better stratify cardiovascular risk.

M. Capel, N. Manito, Carlos Escobar, 2021, Nefrologia.

Risk of outcomes in a Spanish population with chronic kidney disease

M. Capel, N. Manito, Carlos Escobar, 2022, Clinical kidney journal.

Clinical characteristics, management, and one-year risk of complications among patients with heart failure with and without type 2 diabetes in Spain.

C. Escobar, A. Sicras-Mainar, M. Capel, 2021, Revista clinica espanola.

Costs and healthcare utilisation of patients with heart failure in Spain

C. Escobar, M. Capel, N. Manito, 2020, BMC Health Services Research.

Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain

I. Oyagüez, M. Capel, L. Lindner, 2017 .

Economics Analysis of Dapagliflozin Compare to Sulfonylurea in the Treatment of Type 2 Diabetes Mellitus in Spain: Cost of Achieving Composite Endpoints.

M. Capel, L. Cordero, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Primary vs. Secondary Heart Failure Diagnosis: Differences in Clinical Outcomes, Healthcare Resource Utilization and Cost

José Luis Bernal, H. Bueno, L. Vicent, 2022, Frontiers in Cardiovascular Medicine.

Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain

G. Resler, A. Sicras-Mainar, R. Navarro-Artieda, 2020, Journal of medical economics.

Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain

V. Barrios, M. Brosa, M. Capel, 2012, Journal of medical economics.

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus

A. Ciudin, I. Oyagüez, M. Capel, 2019, PharmacoEconomics - Open.

Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study

C. Morales, M. Capel, Carlos Escobar, 2022, BMC Health Services Research.

The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain.

M. Charokopou, M. Capel, J. Sánchez-Covisa, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Economic consequences of the overuse of short-acting beta-adrenergic agonists (SABA) in the treatment of asthma in Spain.

V. Plaza, A. Sicras-Mainar, J. Nuevo, 2021, Journal of investigational allergology & clinical immunology.

Efficiency of naproxen/esomeprazole in association for osteoarthrosis treatment in Spain.

J. Zamorano, Á. Lanas, I. Oyagüez, 2014, Reumatologia clinica.

Efficiency of Naproxen/Esomeprazole in Association for Osteoarthrosis Treatment in Spain

J. Zamorano, Á. Lanas, I. Oyagüez, 2014 .

Clinical Characteristics and Incidence of Hemorrhagic Complications in Patients Taking Factor Xa Inhibitors in Spain: A Long-Term Observational Study

M. Capel, Carlos Escobar, B. Palacios, 2024, Journal of clinical medicine.

Clinical and Economic Consequences of a First Major Bleeding Event in Patients Treated with Direct Factor Xa Inhibitors in Spain: A Long-Term Observational Study

M. Capel, Carlos Escobar, Unai Aranda, 2024, Journal of clinical medicine.